Maintaining and strengthening its position as the No. 1 wholesaler of prescription pharmaceuticals
First written in FY2016. 18 of 26 entries say "Restated". Latest entry: 2026-07-30.
0 other companies' latest entry also says "First stated".
- FY2022-Q3RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company continues to pursue its policy of continuing to win as the No. 1 wholesaler of prescription pharmaceuticals and the three measures of MS functions, specialty products and group logistics. - FY2022-Q2RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company has reaffirmed its policy of continuing to win as the No. 1 wholesaler of prescription pharmaceuticals and the three measures of MS functions, specialty products and group logistics. - FY2022-Q1RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company continues to pursue its policy of continuing to win as the No. 1 wholesaler of prescription pharmaceuticals and the three measures of MS functions, specialty products and group logistics. - FY2021RestatedAnnual report
「The company will further pursue transformation to continue winning as the No. 1 wholesaler of prescription pharmaceuticals.」
The company has reaffirmed its policy of pursuing transformation in order to continue winning as the No. 1 wholesaler of prescription pharmaceuticals. - FY2021-Q3RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company has reaffirmed its policy of continuing to win as the No. 1 wholesaler of prescription pharmaceuticals and the three measures of MS functions, specialty products and group logistics. - FY2021-Q2RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company has reaffirmed its policy of continuing to win as the No. 1 wholesaler of prescription pharmaceuticals and the three key measures of MS functions, specialty products and group logistics. - FY2021-Q1RestatedAnnual report
「To remain the leading wholesaler of prescription pharmaceuticals, our Group continues to pursue the key initiatives set forth in the 19-21 medium-term management plan: further evolution of MS capabilities, a focus on specialty products, and the advancement, efficiency improvement and standardization of Group logistics.」
The company has reaffirmed its policy of continuing to win as the No. 1 wholesaler of prescription pharmaceuticals and the three key measures of MS functions, specialty products and group logistics. - FY2020-Q3RestatedAnnual report
「At the same time, to remain a leading wholesaler of prescription pharmaceuticals, our group is pursuing the further evolution of MS capabilities, a focus on specialty products, and the sophistication, efficiency and standardization of group logistics, all identified as priority measures under the 19-21 Medium-Term Management Plan.」
The company continues to pursue its policy of continuing to win as the No. 1 wholesaler of prescription pharmaceuticals through the three key measures of the new medium-term management plan. - FY2020-Q2RestatedAnnual report
「In addition, to remain a leading wholesaler of prescription pharmaceuticals, our group is pursuing the further evolution of MS capabilities, a focus on specialty products, and the sophistication, efficiency and standardization of group logistics, all identified as priority measures under the 19-21 Medium-Term Management Plan.」
The company continues to strengthen its competitiveness as the No. 1 wholesaler of prescription pharmaceuticals through the three key measures of the new medium-term management plan. - FY2020-Q1RestatedAnnual report
「In addition, to remain a leading wholesaler of prescription pharmaceuticals, our group is pursuing the further evolution of MS capabilities, a focus on specialty products, and the sophistication, efficiency and standardization of group logistics, all identified as priority measures under the 19-21 Medium-Term Management Plan.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company is strengthening its competitiveness through the three key measures of the new medium-term management plan. - FY2019ReframedAnnual report
「The company will further pursue transformation to continue winning as the No. 1 wholesaler of prescription pharmaceuticals.」
The new medium-term management plan describes the strategy as “transformation to continue winning,” rather than the previous focus on maintaining its position as the No. 1 wholesaler and strengthening its business foundation. - FY2019-Q3RestatedAnnual report
「In addition, as the No. 1 wholesaler of prescription pharmaceuticals, our group is further strengthening its business foundation by advancing the reform of sales and logistics functions and pursuing optimization across the group, both identified as priority measures under the 16-18 Medium-Term Management Plan.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company continues to strengthen its foundation through sales and logistics function reform and group-wide optimization. - FY2019-Q2RestatedAnnual report
「In addition, as the No. 1 wholesaler of prescription pharmaceuticals, our group is further strengthening its business foundation by advancing the reform of sales and logistics functions and pursuing optimization across the group, both identified as priority measures under the 16-18 Medium-Term Management Plan.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company continues to strengthen its foundation through sales and logistics function reform and group-wide optimization. - FY2019-Q1RestatedAnnual report
「In addition, as the No. 1 wholesaler of prescription pharmaceuticals, our group is further strengthening its business foundation by advancing the reform of sales and logistics functions and pursuing optimization across the group, both identified as priority measures under the 16-18 Medium-Term Management Plan.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company continues to strengthen its business foundation through sales and logistics function reform and group-wide optimization. - FY2018-Q3RestatedAnnual report
「Against this backdrop, in the wholesale business for prescription pharmaceuticals and other products, we thoroughly pursued efforts to promote distribution reform, a key issue common to the industry, and advanced further strengthening of our business foundation ahead of changes in the operating environment as the No. 1 wholesaler of prescription pharmaceuticals.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company continues to strengthen its business foundation ahead of changes in the operating environment. - FY2018-Q2RestatedAnnual report
「The company further strengthened its business foundation ahead of changes in the operating environment as the No. 1 wholesaler of prescription pharmaceuticals.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company continues to strengthen its business foundation ahead of changes in the operating environment. - FY2018-Q1RestatedAnnual report
「The company further strengthened its business foundation ahead of changes in the operating environment as the No. 1 wholesaler of prescription pharmaceuticals.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company continues to strengthen its business foundation ahead of changes in the operating environment. - FY2017-Q3RestatedAnnual report
「The company further strengthened its business foundation ahead of future changes in the operating environment as the No. 1 wholesaler of prescription pharmaceuticals.」
On the premise of its position as the No. 1 wholesaler of prescription pharmaceuticals, the company continues to strengthen its business foundation ahead of changes in the operating environment. - FY2017-Q1RestatedAnnual report
「The company further strengthened its business foundation ahead of changes in the operating environment as the No. 1 wholesaler of prescription pharmaceuticals.」
The company continues to target maintaining its position as the No. 1 wholesaler of prescription pharmaceuticals and strengthening its foundation ahead of changes in the operating environment. - FY2016First statedAnnual report
「For the fiscal year ending March 2017, the wholesale business for prescription pharmaceuticals and other products was expected to be affected by an average 7.8% reduction in drug prices following the April 2016 revision of medical service fees, among other factors. However, the company would continue to thoroughly pursue the industry-wide most important initiative of “promoting distribution reform” and further strengthen its business foundation ahead of changes in the operating environment as the No. 1 wholesaler of prescription pharmaceuticals.」
The company states that it will respond to changes in the operating environment through distribution reform and business foundation enhancement while maintaining its position as the No. 1 wholesaler.